OS Therapies signed agreements for the commercial manufacture of OST-HER2 as it prepares for an FDA meeting and potential BLA submission. Phase 2b data show OST-HER2 significantly improved 12-month ...

Backed by a $15 million investment, families, funders, and researchers unite to advance long-awaited breakthroughs against this deadly childhood bone cancer "This Break Through Cancer project brings a ...

Lucknow: Doctors at Kalyan Singh Super Speciality Cancer Institute (KSSSCI) successfully performed a complex limb salvage ...

GRAFTON – Haley was a little nervous during her doctor's appointment. She shivered and cowered, but her mood quickly improved. Haley had a leg amputated nearly a year ago after a diagnosis of an ...

OS Therapies Inc. (NYSE:OSTX), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, released survival data on Friday from the Phase 2b trial of its off-the-shelf ...